Business Wire

UPS Unveils Game-Changing UPS ® Global Checkout: No More Surprise Import Fees

26.3.2025 15:30:00 EET | Business Wire | Press release

Share

UPS (NYSE:UPS) today announced the launch of UPS Global Checkout, an exciting new service that makes it even easier for consumers around the world to buy online from shippers around the world. Until now, international purchases often arrived with an unpleasant surprise – an additional bill for unpaid import costs. UPS Global Checkout solves that problem by guaranteeing upfront the amount online shoppers pay in duties, fees and taxes, and eliminating the frustration of unexpected costs at delivery.

UPS is the only global integrated carrier to offer a guaranteed landed cost solution for international shipping that is seamlessly incorporated into its shipping technology, transforming the shopping experience and offering complete transparency on costs. With updates in near real time, the service adjusts to policy changes, international tax laws, duties and tariffs, helping to avoid surprise costs and offering a positive delivery experience. Available in 43 origin countries and delivering to more than 200 destinations worldwide, the service helps businesses of all sizes grow globally by streamlining international shipping.

"With UPS Global Checkout, we’re making international shopping around the world as easy as buying in-store," said Kate Gutmann, EVP and president of International, Healthcare and Supply Chain Solutions at UPS. "Online shoppers can now enjoy full transparency and peace of mind with no surprises, knowing what they pay at checkout is the total cost for a cross-border purchase. This, combined with our total UPS premium delivery experience, benefits our customers – the retailers – by helping to drive additional sales. Given trade shifts around the world, expanding growth opportunities in new markets can now be seamless."

Customs duties, taxes and fees are a significant concern for international shoppers. Every day, tens of thousands of residential deliveries around the world arrive with duties and taxes payable on delivery. And a survey of U.S. and U.K. shoppers found 41% were deterred from buying from an international e-commerce site if the amount of duties and taxes was not crystal clear at checkout.

How UPS Global Checkout changes the game

Guaranteed total landed cost: Purchasers see the total cost, including duties, fees and taxes, before completing their purchase on eligible shipments.*

Enhanced customer experience: No surprise charges at delivery, leading to increased customer satisfaction and encouraging repeat purchases.

Data-driven accuracy: UPS Global Checkout uses artificial intelligence to assess items in the shopping cart and calculate the correct duties and taxes.

Peace of mind: Helps businesses more easily comply with international duties and tariffs.

UPS Global Checkout is one of several new tools UPS offers that simplify cross-border e-commerce. UPS Export Assure offers AI-powered assistance to create export documentation. And UPS Paperless® Invoice helps our customers save time, reduce errors and enhance sustainability by eliminating paper forms.

Learn more about how UPS is helping businesses to ship internationally.

*Terms and conditions apply.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2024 revenue of $91.1 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 490,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. More information can be found at www.ups.com, about.ups.com and investors.ups.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326480482/en/

Contacts

UPS Media Relations: pr@ups.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye